Similar Articles
-
Warfarin Initiation and the Potential Role of Genomic-Guided Dosing
Craig R. Lee- Clinical Medicine & Research November 2005, 3 (4) 205-206;
- DOI: https://doi.org/10.3121/cmr.3.4.205
-
Impact of Age, CYP2C9 Genotype and Concomitant Medication on the Rate of Rise for Prothrombin Time During the First 30 Days of Warfarin Therapy
Russell A. Wilke, Richard L. Berg, Humberto J. Vidaillet, Michael D. Caldwell, James K. Burmester and Michael A. Hillman- Clinical Medicine & Research November 2005, 3 (4) 207-213;
- DOI: https://doi.org/10.3121/cmr.3.4.207
-
PS1-41: Just Add Data: Implementing an Event-Based Data Model for Clinical Trial Tracking
Sharon Fuller, David Carrell and Roy Pardee- Clinical Medicine & Research August 2012, 10 (3) 162;
- DOI: https://doi.org/10.3121/cmr.2012.1100.ps1-41
-
PS1-26: Use of an Electronic Health Record to Facilitate the Enrollment of Patients in Prospective Randomized Clinical Trials: Lessons Learned from STABILITY Trial
Yvette Murley Henry, Kristina Whitmire Evans, Valerie Harkins, Yasmin Mahmud and Peter Berger- Clinical Medicine & Research December 2010, 8 (3-4) 185-186;
- DOI: https://doi.org/10.3121/cmr.2010.943.ps1-26
-
Initiation of Warfarin in Hospitals
Suhail A.R. Doi- Clinical Medicine & Research December 2007, 5 (4) 207-208;
- DOI: https://doi.org/10.3121/cmr.2007.777
-
Absence of Novel CYP4F2 and VKORC1 Coding Region DNA Variants in Patients Requiring High Warfarin Doses
James K. Burmester, Richard L. Berg, Ingrid Glurich, Steven H. Yale, John R. Schmelzer and Michael D. Caldwell- Clinical Medicine & Research November 2011, 9 (3-4) 119-124;
- DOI: https://doi.org/10.3121/cmr.2011.951
-
Absence of Novel CYP4F2 and VKORC1 Coding Region DNA Variants in Patients Requiring High Warfarin Doses
James K. Burmester, Richard L. Berg, Ingrid Glurich, Steven H. Yale, John R. Schmelzer and Michael D. Caldwell- Clinical Medicine & Research May 2011, cmr.2011.951;
- DOI: https://doi.org/10.3121/cmr.2011.951
-
Absence of Novel CYP4F2 and VKORC1 Coding Region DNA Variants in Patients Requiring High Warfarin Doses
James K. Burmester, Richard L. Berg, Ingrid Glurich, Steven H. Yale, John R. Schmelzer and Michael D. Caldwell- Clinical Medicine & Research May 2011, cmr.2011.951;
- DOI: https://doi.org/10.3121/cmr.2011.951
-
Reinitiating Warfarin: Relationships Between Dose and Selected Patient, Clinical and Hospital Measures
Lucas G Leonhard, Richard L Berg, James K Burmester, Joseph J Mazza, John R Schmelzer and Steven H Yale- Clinical Medicine & Research June 2014, cmr.2014.1208;
- DOI: https://doi.org/10.3121/cmr.2014.1208
-
Reinitiating Warfarin: Relationships Between Dose and Selected Patient, Clinical and Hospital Measures
Lucas G Leonhard, Richard L Berg, James K Burmester, Joseph J Mazza, John R Schmelzer and Steven H Yale- Clinical Medicine & Research June 2014, cmr.2014.1208;
- DOI: https://doi.org/10.3121/cmr.2014.1208